Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule'

This article was originally published on Psychedelic Spotlight and appears here with permission.

Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.

A new psilocybin analog created by biopharmaceutical company Cybin shows superior qualities over oral psilocybin for treating mental health disorders, according to pre-clinical data revealed Monday at Wonderland Miami, the largest psychedelic conference ever held.

The company (NYSE: CYBN) (NEO: CYBN) says the data shows the deuterated psilocybin analog—developed as part of its CYB003 program targeting alcohol use disorder (AUD)—can address the challenges associated with oral psilocybin.

Oral psilocybin has proven effective in treating mental health conditions such as major depressive disorder (MDD); however, it has various limitations, including a slow onset of action, extended duration of effect, and variability of response in patients. Cybin’s CYB003 program was focused on creating proprietary analogs to address these challenges while retaining the benefits of …

Full story available on Benzinga.com

More Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule'